(Ociperlimab)Biosimilar Reference Antibody-GS40487 新品

货号：GS40487

Ociperlimab (also known as BGB‑A1217) is an investigational, humanized monoclonal antibody that targets T‑cell immunoreceptor with Ig and ITIM domains (TIGIT), an inhibitory immune checkpoint receptor. By binding with high affinity to TIGIT, it blocks the interaction between TIGIT and its ligands CD155 (PVR) and CD112 (Nectin‑2), thereby reversing the suppression of T‑cell and NK‑cell activity. This blockade aims to enhance anti‑tumor immunity, particularly in the tumor microenvironment. It is being developed as an immune checkpoint inhibitor for the treatment of advanced solid tumors, often in combination with other immunotherapies such as anti‑PD‑1 antibodies (e.g., tislelizumab).